Cleared Traditional

K211156 - CONVIVO In Vivo Pathology Suite

K211156 is the FDA 510(k) clearance for CONVIVO In Vivo Pathology Suite by Carl Zeiss Meditec, AG. It is a Class 2 Neurology device (product code LLZ) cleared through the Traditional 510(k) pathway after a 254-day FDA review.

K211156 · Carl Zeiss Meditec, AG · Neurology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 2021
Decision
254d
Days
Class 2
Risk

K211156 is an FDA 510(k) clearance for the CONVIVO In Vivo Pathology Suite. Classified as System, Image Processing, Radiological within the LLZ classification (a category encompassing advanced image processing and PACS-adjacent software), Class II - Special Controls.

Submitted by Carl Zeiss Meditec, AG (Jena, DE). The FDA issued a Cleared decision on December 29, 2021 after a review of 254 days - an extended review cycle.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 892.2050 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Incremental AI imaging tool. Moderate-to-high equivalence dependency. Overall, this clearance reflects a predicate-aligned approval typical of modern AI radiology extensions - not a novel clinical breakthrough, but a validated iteration within an established regulatory category.

View all Carl Zeiss Meditec, AG devices

Submission Details

510(k) Number K211156 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 19, 2021
Decision Date December 29, 2021
Days to Decision 254 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
106d slower than avg
Panel avg: 148d · This submission: 254d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code LLZ System, Image Processing, Radiological
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 892.2050
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.

Regulatory Consultant

Carl Zeiss Meditec, Inc.
Maria Golovina

The regulatory consultant manages the 510(k) submission process on behalf of the applicant - coordinating technical documentation, predicate strategy and FDA communications. Identifying the consultant behind a submission is a key signal for competitive regulatory intelligence.

Regulatory Peers - LLZ System, Image Processing, Radiological

All 1090
Devices cleared under the same product code (LLZ) and FDA review panel - the closest regulatory comparables to K211156.
UNiD Spine Analyzer
K212005 · Medicrea International, Inc. · Jan 2022
AIBOLIT 3D+
K211443 · Aibolit Technologies, LLC · Jan 2022
VUZE System
K210830 · Vuze Medical , Ltd. · Jan 2022
Claritas iPET
K213140 · Claritas Healthtech Pte, Ltd. · Dec 2021
Libby IAAA v1.0
K210931 · Dyad Medical, Inc. · Dec 2021
Brainlab Elements, Brainlab Elements Contouring, Brainlab Elements Fibertracking, Brainlab Elements Image Fusion, Brainlab Elements Image Fusion Angio
K212420 · Brainlab AG · Dec 2021